Research Grant Announcement
HOPA Research Fund Award

The call for LOI's has now closed.

The HOPA Research Committee announces a request for submission of letters of intent (LOIs) for the 2020 HOPA Research Award. The HOPA Research Committee will fund at least two, but up to three grants based on the stated scope of work. A total of $100,000 is available to be awarded to up to three grants in 2020 through a competitive peer-review process described below. HOPA aims to fund at least one practice-based and one basic/translational study.


The research fund is intended to support a hematology/oncology pharmacy practice research project with subsequent publication that aligns closely with the HOPA strategic plan to demonstrate the value of hematology/ oncology pharmacy practice. Pharmacy practice is broadly defined to include areas of research such as: clinical or patient outcomes, surveys, patient safety, standards validation, and basic/translational science applications. Multiple institutions may be involved in the project, and a project with co-PIs are allowed. A subsequent publication resulting from the research project is expected within a year of the study completion.

Research proposal submitted to this program must align with the HOPA strategic plan.


The grant is open to all full* members of HOPA, with noted stipulations for members of the HOPA Grant Reviewers, Basic and Translational Sciences, and Practice Outcomes & Professional Benchmarking Committees, and HOPA Board Members. Members of the HOPA Research Committees and Board may submit a grant proposal as a co-investigator or member of the research team, but may not be listed as the primary investigator. 

Applying HOPA Research Committees and Board Members may not receive any portion of the grant monies in salary or any other direct way, but may be listed as an author on produced publications. (Refer to Research Grants Program Eligibility Statement).

*Please refer to the membership categories for eligibility.

Application Process

  1. Letters must be submitted electronically to This email address is being protected from spambots. You need JavaScript enabled to view it..
  2. Letters of Intent (LOI) should concisely explain how the proposed research supports pharmacy practitioners and advances hematology/oncology pharmacy to optimize the care of individuals affected by cancer. 
  3. The LOIs will be reviewed by members of the HOPA Grant Reviewers Committee and a decision regarding acceptance for development into a full grant proposal will be sent to applicants. Concepts presented in the LOI that do not address stated objectives and/or criteria of the request for applications (RFA) will be returned with a letter of explanation and not considered further.
  4. Submitters of LOIs that are approved for development will be invited to prepare a full grant proposal using the current NIH format. Refer to for format. Grant applications must be submitted electronically as a single PDF file to This email address is being protected from spambots. You need JavaScript enabled to view it..
  5. All applicants will receive written feedback regarding review of their application.
  6. Click here for the Letter of Intent (LOI) format details.
  7. Click here for the full proposal format details.
  8. Here you can find a list of Frequently Asked Questions.


Award Administration

  1. Funds will be released to the investigator in their entirety, contingent upon Institutional Review Board (IRB) approval, unless stipulations are placed on the disbursement by the HOPA Grant Reviewers Committee in its review of the application.
  2. The awardee is required to submit a report of progress every six months to This email address is being protected from spambots. You need JavaScript enabled to view it..
  3. The awardee is expected to present the results of their research at the HOPA annual meeting. This presentation is expected to occur no later than two years after the release of the research funds. The results of the study are expected to be submitted for publication in a peer-reviewed biomedical print or online journal. The Hematology/Oncology Pharmacy Association is to be acknowledged in any presentation or publication for its support of the research.
  4. There is no provision for indirect costs in this research grant (refer to FAQ for definition of “indirect cost”). A travel budget is expected to be included in the proposal to allow the presentation of the results at the HOPA annual meeting. Additional travel funds should be justified in the context of the needs of the project. Capital equipment purchases are not allowed in this grant.
  5. All unused funds remaining from the grant 12 months after the disbursement must be returned to HOPA. The investigator may petition the HOPA Research Committee for an extension for use of the funds. This request for an extension must be made at least three months before the expiration of the grant. Progress reports are due to the Grant Administrator and Grant Reviewer Committee Chairs at the six, nine, and twelve week marks.

Current and Past Research Grantees  >